摘要
目的考察泻痢消片对大鼠实验性结肠炎的保护作用。方法雄性SD大鼠随机分为6组,每组10只。除空白对照组外,其他组用2,4-二硝基氯苯和醋酸灌肠的方法制备大鼠结肠炎模型。泻痢消高、中、低剂量组分别给予泻痢消溶液0.28,0.56,1.12 g.kg-1,阳性对照组给予柳氮磺吡啶(0.27 g.kg-1),造模次日开始给药,每天1次,连续14 d。对大鼠疾病活动指数(DAI)进行评分,测定结肠组织中核因子κBp65(NF-κBp65)表达和髓过氧化物酶(MPO)水平。结果泻痢消高、中、低剂量组能够降低大鼠DAI评分,降低结肠组织中NF-κBp65表达和MPO水平(P<0.05或P<0.01)。结论泻痢消可以减轻肠道炎症,对实验性结肠炎有良好疗效。
Objective To evaluate the protective effect of xielixiao tablets on experimental colitis in rats. Methods Sixty male SD rats were separated into 6 groups randomly. The colitis model was established by rectal injection with dinitrochlorohenzene and acetic acid. xilixiao tablets （0.28,0.56,1.12 g · kg^-1） or salazosulfapyridine （0.27 g · kg^-1） were administered intragastrically ,once daily for 14 days. The disease activity index （DAI）, Myeloperoxidase（MPO） and NF-KBp65 expression of colon were measured. Results In xielixiao-treated rats, DAI, MPO and NF-KBp65 expression were decreased, compared to the model controls. Conclusion Xielixiao shows benefits on experimental colitis by alleviating intestinal inflammation.
出处
《医药导报》
CAS
北大核心
2013年第7期881-884,共4页
Herald of Medicine
